Concepedia

Author

Paul W.A. Janssen

St. Antonius ZiekenhuisORCID

Also Known As

Janssen, Paul W., Johannes Kelder, P. W. A. Janssen, P.W.A. Janssen, Paul Janssen, Paul W. A. Janssen, Paul W. Janssen, Paul W.A. Janssen, Paul WA Janssen, Tobias Geisler

43

Publications

2.1K

Citations

18

H-Index

18

Concepts

All Affiliations

St. Antonius ZiekenhuisUniversity Medical Center UtrechtMeander Medisch CentrumIsalaUniversity College London
PW

About

Paul W.A. Janssen is an author at St. Antonius Ziekenhuis specializing in medicine, cardiovascular disease, and coronary heart disease.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

123

2

Public Health

1

1

81

3

Epidemiology

1

1

81

4

Medical Laboratory Science

1

1

19

5

Pharmacology

1

1

23

Paul W.A. Janssen

×

13

Publications

1.4K

Citations

13

H-Index

YearCitations

A Genotype-Guided Strategy for Oral P2Y <sub>12</sub> Inhibitors in Primary PCI

Daniel M.F. Claassens, Gerrit J.A. Vos, Thomas O. Bergmeijer,

New England Journal of Medicine

2019

597

ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting

Stefanie Schüpke, Robert A. Byrne, Jurriën M. ten Berg,

European Heart Journal

2015

423

CYP2C19 genotype–guided antiplatelet therapy in ST-segment elevation myocardial infarction patients—Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study

Thomas O. Bergmeijer, Paul W.A. Janssen, Jurjan C. Schipper,

American Heart Journal

2014

81

Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting (POPular CABG)

Laura M. Willemsen, Paul W.A. Janssen, Joyce Peper,

Circulation

2020

63

Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial

Willem J.M. Dewilde, Paul W.A. Janssen, Johannes C. Kelder,

EuroIntervention

2015

50

Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older—rationale and design of the POPular AGE study

Khalid Qaderdan, Maycel Ishak, Antonius A.C.M. Heestermans,

American Heart Journal

2015

48

Incidence and Causes for Early Ticagrelor Discontinuation: A “Real-World” Dutch Registry Experience

Thomas O. Bergmeijer, Paul W.A. Janssen, Mathijs van Oevelen,

Cardiology

2017

39

Perioperative management of antiplatelet treatment in patients undergoing isolated coronary artery bypass grafting in Dutch cardiothoracic centres

Paul W.A. Janssen, Daniel M.F. Claassens, Laura M. Willemsen,

Netherlands Heart Journal

2017

33

Feasibility and Implementation of <i>CYP2C19</i> Genotyping in Patients Using Antiplatelet Therapy

Thomas O. Bergmeijer, Gerrit J.A. Vos, Daniel M.F. Claassens,

Pharmacogenomics

2018

26

Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype

Daniel M.F. Claassens, Thomas O. Bergmeijer, Gerrit J.A. Vos,

Circulation Cardiovascular Interventions

2021

26

Page 1